Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
-$0.04 today
- Market cap
- $206.36M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 6.78M
Average 1.19M
Returns on capital
Lineage Cell Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-142.6%
avg -47.5%
ROIC
-19.7%
avg -32.5%
ROA
-56.4%
avg -22.9%
Analysis
ROIC is currently the strongest return metric at -19.7% versus its period average of -32.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Brian Culley | Chief Executive Officer, President & Director | USD 1.23M | 55 | — | — |
Jill Ann Howe | Chief Financial Officer | USD 718K | 50 | 1.05M | 0.42% |
George A. Samuel | General Counsel & Company Secretary | USD 690.3K | 45 | — | — |
Harold D. Waitz | Vice President of Regulatory Affairs & Quality Control | USD 90K | 84 | 0 | <0.01% |
Alexandra Hernandez | Senior Director of Finance & Controller | — | — | 29.19K | 0.01% |
Charlotte Hubbert | Vice President of Corporate Strategy & Development | — | — | — | — |
Priyantha Herath | Senior VP & Head of Clinical Operations | — | — | — | — |
Rami Skaliter | Chief Executive Officer of Cell Cure Neurosciences | — | 68 | — | — |
Ioana C. Hone | Director of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$24,375.00
Sells
0
$0.00
Net Transaction Value
+$24,375.00
Net buying
Most Active
Culley Brian M
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 12, 26Mar 12, 2026 | Culley Brian M Direct | Buy | $24.4K$24,375.00 |
Summary
Insiders reported 1 buys worth $24,375.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24,375.00. Culley Brian M was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -0.3% | +103.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.3% over three years. Forward estimates point to Revenue at +103.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Lineage Cell Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LCTX's management, answered from reported figures.
Who manages LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) lists 9 active executives. The top listed executive is Alexandra Hernandez, Senior Director of Finance & Controller.
Are LCTX insiders buying or selling?
Recent insider activity shows net buying of $45.36M.
Continue the stock analysis
Jump to another research area for this company.